Dialysis News and Research RSS Feed - Dialysis News and Research

When your kidneys are healthy, they clean your blood. They also make hormones that keep your bones strong and your blood healthy. When your kidneys fail, you need treatment to replace the work your kidneys used to do. Unless you have a kidney transplant, you will need a treatment called dialysis.

There are two main types of dialysis: hemodialysis and peritoneal dialysis. Both types filter your blood to rid your body of harmful wastes, extra salt and water. Hemodialysis does that with a machine. Peritoneal dialysis uses the lining of your abdomen, called the peritoneal membrane, to filter your blood. Each type has both risks and benefits. They also require that you follow a special diet. Your doctor can help you decide the best type of dialysis for you.
FMNCA's disaster response program makes difference in patients' lives during Super Storm Sandy

FMNCA's disaster response program makes difference in patients' lives during Super Storm Sandy

Fresenius Medical Care North America, a division of Fresenius Medical Care and North America's largest provider of kidney care, hospitalist services and renal products, today hailed a new study by the Department of Health and Human Services this week showing that dialysis patients who received treatments immediately before Super Storm Sandy experienced a much better survival rate and less frequent visits to the hospital. [More]
DaVita Kidney Care offers recipes to help CKD patients maintain healthy diet during Fourth of July weekend

DaVita Kidney Care offers recipes to help CKD patients maintain healthy diet during Fourth of July weekend

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, offers recipes that can help people with chronic kidney disease (CKD) maintain a healthy diet during the Fourth of July weekend. [More]

DaVita HealthCare Partners expands office space in Lower Downtown Denver

DaVita HealthCare Partners Inc., one of the largest and most innovative health care communities, today announced the company has expanded its office space to include two more floors of the Gates Building, located at 1551 Wewatta Street in Lower Downtown Denver. [More]

DaVita HealthCare Partners honored as 2015 Top Green Company in the U.S.

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, today announced that the company was recognized by Newsweek Green Rankings as a 2015 Top Green Company in the U.S. The company has appeared on the list every year the award program has run since 2009. [More]
Falcon Physician wins Gold Stevie Award in Information Technology Department of the Year category

Falcon Physician wins Gold Stevie Award in Information Technology Department of the Year category

Falcon Physician was presented with a Gold Stevie Award in the Information Technology Department of the Year category at the 13th Annual American Business Awards in Chicago. [More]
DaVita Kidney Care recognizes June as National Men's Health Month

DaVita Kidney Care recognizes June as National Men's Health Month

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, recognizes the month of June as National Men's Health Month and the importance of bringing awareness to the health care issues that affect men. [More]
DaVita's HealthCare Partners division celebrates National Men's Health Month

DaVita's HealthCare Partners division celebrates National Men's Health Month

HealthCare Partners, a division of DaVita HealthCare Partners Inc., celebrates the month of June – National Men's Health Month – by recognizing the importance of bringing awareness to the health care issues that affect men. [More]
Study reveals how geography affects the survival of people with end-stage kidney disease

Study reveals how geography affects the survival of people with end-stage kidney disease

The notion that geography often shapes economic and political destiny has long informed the work of economists and political scholars. Now a study led by medical scientists at Johns Hopkins reveals how geography also appears to affect the very survival of people with end-stage kidney disease in need of dialysis. [More]
First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace. [More]
EMS Find inks LOI to acquire Page Out

EMS Find inks LOI to acquire Page Out

EMS Find, Inc. today announced that the company has signed a Letter Of Intent ("LOI") to acquire Page Out – interactive platform designed to streamline the emergency response process and provides management with real time status on where and when team members are responding to emergency and dispatch. [More]
Patient survival rates for home hemodialysis significantly higher than peritoneal dialysis

Patient survival rates for home hemodialysis significantly higher than peritoneal dialysis

NxStage Medical, Inc. is encouraging patients to take control of their dialysis therapy and consider home hemodialysis in the wake of a new study that found patient survivability rates are significantly higher with home hemodialysis (HHD) than peritoneal dialysis (PD). [More]
Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022. [More]
Link between poverty and kidney disease changes over time, shows study

Link between poverty and kidney disease changes over time, shows study

Poverty is known to be a strong risk factor for end-stage kidney disease. Now, a first of-its-kind study has found that the association between poverty and kidney disease changes over time. [More]

Link between poverty and kidney disease changes over time, study finds

Poverty is known to be a strong risk factor for end-stage kidney disease. Now, a first of-its-kind study has found that the association between poverty and kidney disease changes over time. [More]
Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"). [More]

DaVita Kidney Care releases list of top 10 U.S. travel destinations for dialysis patients

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today released a list of the top 10 U.S. travel destinations for dialysis patients. [More]
Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx. [More]
Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures. [More]
Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. [More]
New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials." [More]
Advertisement